Time to ‘get real’: preliminary insights into the long-term management of schizophrenia

REFERENCES

• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000; 177:212–17.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB . Practice guideline for the treatment of patients with schizophrenia, second. American Journal of Psychiatry 2004; 161:1–56.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J . World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. The World Journal of Biological Psychiatry 2005; 6:132–191.
   PubMed Web of Science ®Google Scholar
• Miller AL, Crismon ML, Rush AJ . The Texas medication algorithm project: clinical results for schizophrenia. Schizophrenia Bulletin 2004; 30:627–47.
   PubMed Web of Science ®Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry 2005; 39:1–30.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update of Clinical Guideline 1): Clinical Guideline 82. 2009; NHS: London.
   Google Scholar
• Malhi GS, Adams D, Plain J, Coulston C, Herman M, Walter G. Clozapine and cardio-metabolic health in chronic schizophrenia: Correlations and consequences in a clinical context. Australasian Psychiatry 2010; 18; 32–41.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J . World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. The World Journal of Biological Psychiatry 2006; 7:5–40.
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, and Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophrenia Research 2009; 110:1–23.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Green MJ, Fagiolini A, Peselow ED, Kumari V. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disorders 2008; 10:215–230.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Safferman AZ, Pollack S . Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 1994; 151:1744–52.
   PubMed Web of Science ®Google Scholar
• Bitter I, Dossenbach MR, Brook S . Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004; 28:173–80.
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45:789–96.
   PubMed Web of Science ®Google Scholar
• Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When symptoms persist: clozapine augmentation strategies. Schizophrenia Bulletin 2001; 27:615–28.
   PubMed Web of Science ®Google Scholar
• Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical anti-psychotics for hospital inpatients in the United Kingdom. International Journal of Psychiatry in Clinical Practice 2000; 4:41–46.
   PubMed Web of Science ®Google Scholar
• Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety 2008; 31:7–20.
   PubMed Web of Science ®Google Scholar
• Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19:843–72.
   PubMed Web of Science ®Google Scholar
• Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Safety 2006; 29:95–118.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Moss B, Walter G. To medicate or not to medicate, when diagnosis is in question: decision-making in first episode psychosis. Australasian Psychiatry 2010 Feb 17 [Epub ahead of print]
   Web of Science ®Google Scholar